The role of magnesium supplement in laryngopharyngeal reflux disease




Laryngopharyngeal reflux disease, Magnesium supplements, GERD, Reflux treatment


Background: Laryngopharyngeal reflux disease (LPRD) is one of the most prevalent upper gastrointestinal disorder encountered in clinical practice and its optimal treatment is not standardized. The role of magnesium in the human body functions is often underestimated. Since magnesium (Mg) plays a major role in the regulation of smooth muscle contractionby relaxing the pyloric sphincter and enhancing gastric emptying, thereby decreasing the pressure on the LES, it was hypothesized that adding magnesium supplements along with the regular treatment for LPRD, can improve LPRD symptoms. Magnesium has a neutralizing action on the gastric acid and therefore, it may be pertinent to achieve optimal Mg intakes in patients with LPRD.

Methods: This is a prospective study done over a period of 1 year conducted in a tertiary care hospital in central India in patients presenting with LPRD of the age group 18-65 years.  

Results: The study patients were divided into two groups-one treated with esmoprazole 40 mg capsules and alginate syrup and the other with esmoprazole capsules, alginate syrup and magnesium glycinate (250 mg) supplement. Both the groups showed appreciable improvement in their mean reflux symptom index (RSI) and reflux finding score (RFS) at 1 month and 3 months follow-up. Females showed a higher preponderance than males in the disease, symptoms and the mean RSI and RFS score.

Conclusions: Addition of magnesium supplements along with the regular treatment for LPRD, can improve LPRD symptoms and should be considered in the treatment protocol of LPRD.


Sataloff RT. Gastroesophageal reflux related chronic laryngitis. Commentary. Arch Otolaryngol Head Neck Surg. 2010;136(9):914-5.

Lynch KL. Gastroesophageal Reflux Disease (GERD) in Merck Manual Professional Version. 2019. Available at: https://www.msdmanuals .com/en-in/professional/gastrointestinal-disorders/ esophageal-and-swallowing-disorders/gastroesopha geal-reflux-disease-gerd. Assessed on 24 September 2021.

Simic PJ. Acid Reflux (GERD). E-medicine health. 2019. Available at: https://www.emedicinehealth. com/acid_reflux_disease_gerd/article_em.htm. Accessed on 24 September 2021.

American Gastroenterological Association website. Understanding heartburn and reflux disease. 2020. Available at: phageal-reflux-disease-gerd/. Accessed on 24 September 2021.

Allgrove J. Physiology of calcium, phosphate and magnesium. Endocr Dev. 2009;16:8-31.

Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol. 2008;24:230-5.

Shils ME. Experimental human magnesium depletion. Medicine (Baltimore). 1969;48:61-85.

Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36:405-13.

Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: clinical case series. QJM. 2010;103:387-95.

Institute of Medicine & Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academies Press. 1997.

Bough I, Sataloff R, Castell D, Hills J, Gideon R, Spiegel J. Gastroesophageal reflux laryngitis resistant to omeprazole therapy. J Voice. 1995;9:205-11.

Hogan W, Shaker R. Medical treatment of supraesophageal complications of gastroesophageal reflux disease. Am J Med. 2001;111(8A):197-201.

Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(4):1-78.

Potter JD, Robertson SP, Johnson JD. Magnesium and the regulation of muscle contraction. Fed Proc. 1981;40(12):2653-6.

Remes-Troche JM, Sobrino-Cossío S. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD). Clin Drug Investig. 2014;34(2):83-93.

Hein J. Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro- oesophageal reflux disease: a randomized, double-blind, con- trolled, multicentre trial. Clin Drug Investig. 2011;31(9):655-64.

Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46(2):93-114.

Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448-57.

Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam Ong S, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore). 2019;98:e17788.

Nagahama K, Nishio H, Yamato M, Takeuchi K. Orally administered L-arginine and glycine are highly effective against acid reflux esophagitis in rats. Med Sci Monit. 2012;18(1):9-15.

Dai Q, Cantwell MM, Murray LJ, Dietary magnesium, calcium: magnesium ratio and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study. Br J Nutr. 2016;115(2):342-50.






Original Research Articles